Amiodarone-induced hyponatremia in an elderly patient

Özdemir, Öner; Soyaltın, Utku Erdem; Akar, Harun; Ekinci, Ferhat; Komaç, Andaç; Elyiğit, Faruk

doi:10.1016/j.eurger.2015.03.009

Cited by 4 publications

(3 citation statements)

References 9 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of reported cases were seen among elderly male patients, and most patients had comorbid conditions such as hypertension, hyperlipidemia, congestive heart failure, and arrhythmia, with the duration of amiodarone therapy ranging from less than 24 hours to 5 years before the development of hyponatremia. [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21] The adverse effects reported in these cases include altered mental status, torsades de pointes, dizziness, hypotension, generalized weakness, and loss of appetite. Adrenal insufficiency and thyroid dysfunction was ruled out in all the reported cases.…”

Section: Discussionmentioning

confidence: 99%

Amiodarone-Induced Hyponatremia in An Elderly Patient: A Rare Case Report

Mahadevappa

Jodiya

Chalasani

et al. 2021

Journal of Pharmacy Practice

View full text Add to dashboard Cite

Amiodarone is an antiarrhythmic drug belonging to Vaughan-Williams Class III with additional Class IV effects, which is known to cause many adverse drug reactions (ADRs) necessitating close monitoring. In about 20% of patients, their therapy is discontinued due to adverse effects such as hepatic impairment, thyroid dysfunction, and several pulmonary complications. Although dyselectrolytemia is a common adverse reaction reported with many cardiac medications, the incidence of hyponatremia associated with amiodarone intake is not reported widely in the literature. We are reporting a case of a 73-year-old female patient, with hypertension and ischemic heart disease (IHD) receiving oral amiodarone, presenting with severe hyponatremia, requiring recurrent hospitalization. Amiodarone was found to be responsible after evaluating for the possible causes of hyponatremia. As the incidence of amiodarone-associated hyponatremia is unknown, and not many cases are reported, this case report serves to sensitize the clinician to consider amiodarone-induced hyponatremia as one of the differential diagnoses in cases of unexplained hyponatremia.

show abstract

Section: Discussionmentioning

confidence: 99%

Amiodarone-Induced Hyponatremia in An Elderly Patient: A Rare Case Report

Mahadevappa

Jodiya

Chalasani

et al. 2021

Journal of Pharmacy Practice

View full text Add to dashboard Cite

show abstract

“…In the published medical literature, only 17 cases of amiodarone-induced hyponatremia have been reported, to our knowledge (Table 3). [8][9][10][11][12][13][14][15][16][17][18][19][20][21] The affected patients were predominantly male (n = 13) and elderly (range: 58-88 years, median: 68 years). Either atrial fibrillation or ventricular arrhythmia was the indication to start amiodarone in all 17 cases.…”

Section: Discussionmentioning

confidence: 99%

Amiodarone-induced Hyponatremia: A Case Report and a Review of the Literature

Barham

Zeayter

Safadi

et al. 2018

J Innov Cardiac Rhythm Manage

View full text Add to dashboard Cite

show abstract

“…9) To the best of our knowledge, 16 cases of amiodarone-induced SIADH have been published thus far. [10][11][12][13][14][15] Hyponatremia is an electrolyte disorder frequently seen in severe HF, especially in the context of diuretic use. Tolvaptan, a vasopressin 2 receptor antagonist, is an aquaretic agent, and its effectiveness for severe HF even in LVAD patients has been reported.…”

Section: Discussionmentioning

confidence: 99%

Amiodarone-Induced Hyponatremia Masked by Tolvaptan in a Patient with an Implantable Left Ventricular Assist Device

2017

View full text Add to dashboard Cite

A 43-year-old man was referred to our hospital in June 2014 because of severe heart failure. He was diagnosed with familial dilated cardiomyopathy and was administered oral tolvaptan and amiodarone for atrial and ventricular tachycardia. Since up-titration of carvedilol had failed and he was dependent on dobutamine, a left ventricular assist device (LVAD) was implanted. Tolvaptan and furosemide were both discontinued after LVAD implantation and he was discharged from the hospital. Thirteen months later, he was hospitalized for lethargy and hyponatremia of 108 mEq/L, with an antidiuretic hormone level of 2.5 pg/mL, which suggested syndrome of inappropriate antidiuretic hormone secretion (SIADH). We discontinued amiodarone and administered fludrocortisones. However, hyponatremia persisted for a few more days, eventually resulting in delirium and damage to the LVAD driveline. He received an urgent pump exchange and hyponatremia was gradually improved. We considered the possibility that amiodarone-induced SIADH was masked by tolvaptan therapy before LVAD implantation.

show abstract

Amiodarone-induced hyponatremia in an elderly patient

Cited by 4 publications

References 9 publications

Amiodarone-Induced Hyponatremia in An Elderly Patient: A Rare Case Report

Amiodarone-Induced Hyponatremia in An Elderly Patient: A Rare Case Report

Amiodarone-induced Hyponatremia: A Case Report and a Review of the Literature

Amiodarone-Induced Hyponatremia Masked by Tolvaptan in a Patient with an Implantable Left Ventricular Assist Device

Contact Info

Product

Resources

About